Skip to content
PeptideAgent

DSIP (delta sleep-inducing peptide) regulatory status

Current status of DSIP (delta sleep-inducing peptide) in the United States: Not eligible for compounding. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of DSIP (delta sleep-inducing peptide)?

Regulatory: Not eligible for compoundingWADA: WADA prohibitedVerified: Verified Sep 27, 2026
FDA and compounding
Not an FDA approved drug. DSIP was placed on the FDA 503A Category 2 list in 2023 and was one of the peptides FDA now lists as withdrawn from 503A Category 2 (page current as of April 22, 2026) after the nominations were withdrawn. At the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting the committee voted against adding DSIP to the 503A bulks list, citing inadequate evidence of safety and effectiveness. Pending FDA's final action, compounding pharmacies have no basis to compound it. Not eligible for 503B outsourcing.
WADA
WADA prohibited
Access path
  1. Not available as an FDA approved product.
  2. Not compounded following the July 2026 advisory committee vote against listing.
  3. Products labeled research use only are not lawful for human use and are not verified for purity.

Full DSIP (delta sleep-inducing peptide) page: evidence, dosing in the literature, and sources

How has the status of DSIP (delta sleep-inducing peptide) changed over time?

  1. PCAC

    PCAC votes against adding DSIP to the 503A bulks list

    At the July 23 to 24, 2026 meeting, the Pharmacy Compounding Advisory Committee did not recommend delta sleep-inducing peptide (DSIP) for the 503A bulks list, citing the state of the evidence. FDA makes the final determination by rulemaking.

    Regulatory: Not eligible for compoundingSource: Pharmacy Compounding Advisory Committee
  2. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, revised in April 2026 and current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. A withdrawn substance is no longer in 503A Category 2, but withdrawal is not an approval and does not place a substance on the 503A bulks list; a 503A pharmacy still needs a listing before it may compound it. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

    Regulatory: Removed from Category 2 (Apr 2026)Source: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)
  3. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

    Regulatory: Not eligible for compoundingSource: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for DSIP (delta sleep-inducing peptide) and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026